Results 211 to 220 of about 120,218 (287)

Blocking the CTLA-4 and PD-1 pathways during pulmonary paracoccidioidomycosis improves immunity, reduces disease severity, and increases the survival of infected mice [PDF]

Nycolas Willian Preite, Bruno Montanari Borges, Valéria de Lima Kaminski, Marina Caçador Ayupe, Leonardo Mandu Gonçalves, Bianca Vieira dos Santos, Dennyson Leandro M. Fonseca, Igor Salerno Filgueiras, Caio Loureiro Salgado, Sandra Márcia Muxel, Otávio Cabral-Marques, Denise Morais da Fonseca, Flávio V. Loures, Vera Lúcia Garcia Calich   +13 more
openalex   +1 more source

Anti-CTLA-4 Monoclonal Antibody [PDF]

, 2020
openaire   +1 more source

Decoding Senescence‐Driven Heterogeneity in Early‐Onset Colorectal Cancer for Prognostic and Therapeutic Stratification

Cancer Science, EarlyView.
We uncovered pronounced and heterogeneous tumor senescence in EOCRC, independent of age. By integrating multi‐omics and single‐cell analyses, we developed EO‐Senscore, a prognostic tool that stratifies patients by immune phenotype and therapy response, enabling precision treatment using immunotherapy or senolytic agents. ABSTRACT Early‐onset colorectal
Du Cai, Mingru Mai, Rende Huang, Haoning Qi, Xingzhi Feng, Qianling Gao, Yinmeng Zhang, Chenghang Li, Xiaojian Wu, Yize Mao, Zihuan Yang, Feng Gao   +11 more
wiley   +1 more source

pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies. [PDF]

Proc Natl Acad Sci U S A
Zhang M, Li J, Yan K, Zhou H, Mei S, Wang B, Li D, Du X, Liu M, Zhang P, Fields JK, Ye L, Zheng P, Liu Y, Lenardo MJ, Zhang Y.   +15 more
europepmc   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, EarlyView.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source

Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategy. [PDF]

Front Immunol
Tan H, Shah NUH, He B, Liu T, Li T, Liu M, Gu Y, Zhi C, Ou Y, Huang J, Li M, Zuo S, Chen D, Qin R, Yang H, Li X, Lian H, Wu Q, Leidner R, Chen R, Yang A, Yang L, Zhang Z.   +22 more
europepmc   +1 more source

AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes

Clinical &Experimental Allergy, EarlyView.
ABSTRACT The AllergoOncology field brings together the study of allergic and cancer immune responses, having evolved from early epidemiological studies that reported inverse associations between allergies, IgE and cancer risk. Insights from studying allergic inflammation are revealing previously unappreciated immune mechanisms that confer protective ...
Jakub Zydron, Anishaa Balaji, Jitesh Chauhan, Jack Alder, Xinyi Chen, Anna M. F. Wiegman, Aurelie Poli, Joanna Jacków‐Malinowska, Jack Cheeseman, Daniel I. R. Spencer, James McDonnell, James Spicer, Alexandra J. McCraw, Sophia N. Karagiannis   +13 more
wiley   +1 more source

Blood expression of CTLA-4, PD-1, and PD-L1 as potential prognostic and diagnostic markers for breast cancer: a systematic review. [PDF]

Discov Oncol
Niusha M, Hajazimian S, Soltani N, Goleij P, Pagard P, Oruji F, Behroozi J, Shabani S, Isazadeh A, Baradaran B.   +9 more
europepmc   +1 more source

CTLA-4: Checkpoints beyond the membrane

Molecular Therapy
openaire   +2 more sources

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source